Savara Inc. (SVRA)
Largest Insider Buys in Sector
SVRA Stock Price History Chart
SVRA Stock Performance
About Savara Inc.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Insider Activity of Savara Inc.
Over the last 12 months, insiders at Savara Inc. have bought $346,672 and sold $1.18M worth of Savara Inc. stock.
On average, over the past 5 years, insiders at Savara Inc. have bought $3.32M and sold $626,934 worth of stock each year.
Highest buying activity among insiders over the last 12 months: RAMSAY DAVID A (director) — $575,200. McCracken Joseph S (director) — $59,072.
The last purchase of 20,000 shares for transaction amount of $59,072 was made by McCracken Joseph S (director) on 2024‑11‑19.
List of Insider Buy and Sell Transactions, Savara Inc.
| 2024-12-16 | Sale | CHIEF EXECUTIVE OFFICER | 54,702 0.0322% | $3.31 | $180,828 | -1.07% | ||
| 2024-12-16 | Sale | Chief Financial Officer | 25,000 0.0148% | $3.33 | $83,278 | -1.07% | ||
| 2024-12-16 | Sale | director | 8,000 0.0047% | $3.32 | $26,569 | -1.07% | ||
| 2024-11-19 | director | 20,000 0.0117% | $2.95 | $59,072 | +6.48% | |||
| 2024-11-18 | director | 100,000 0.0566% | $2.88 | $287,600 | +2.92% | |||
| 2023-12-28 | Sale | CHIEF EXECUTIVE OFFICER | 84,000 0.0609% | $4.71 | $395,900 | -8.48% | ||
| 2023-12-28 | Sale | CHIEF FINANCIAL OFFICER | 10,000 0.0072% | $4.71 | $47,131 | -8.48% | ||
| 2023-12-28 | Sale | director | 93,843 0.068% | $4.71 | $442,291 | -8.48% | ||
| 2023-07-17 | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.17% | |||
| 2023-07-17 | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.17% | |||
| 2023-07-17 | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.17% | |||
| 2023-07-17 | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.17% | |||
| 2023-07-17 | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.17% | |||
| 2023-07-17 | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.17% | |||
| 2023-07-17 | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.17% | |||
| 2023-07-17 | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.17% | |||
| 2023-07-17 | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.17% | |||
| 2023-07-17 | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.17% | |||
| 2023-06-26 | Chief Medical Officer | 6,500 0.0047% | $2.93 | $19,045 | +53.21% | |||
| 2023-05-26 | director | 37,124 0.024% | $2.63 | $97,599 | +44.36% |
Insider Historical Profitability
| RAMSAY DAVID A | director | 2323642 1.354% | $3.23 | 52 | 0 | +40.1% |
| Pauls Matthew | CHIEF EXECUTIVE OFFICER | 1536379 0.8952% | $3.23 | 10 | 2 | <0.0001% |
| Lowrance David L | Chief Financial Officer | 381005 0.222% | $3.23 | 3 | 12 | +23.24% |
| McCracken Joseph S | director | 210837 0.1229% | $3.23 | 3 | 0 | +29.35% |
| SANDELL SCOTT D | 10 percent owner | 24471264 14.2591% | $3.23 | 1 | 0 |
Institutional Investor Ownership
| Nea Management Company Llc | $121.87M | 14.88 | 24.47M | 0% | +$0 | 0.57 | |
| Bain Capital Life Sciences Investors Llc | $72.54M | 8.86 | 14.57M | +2.34% | +$1.66M | 5.84 | |
| Tcg Crossover Management Llc | $49.8M | 6.08 | 10M | 0% | +$0 | 0.08 | |
| JENNISON ASSOCIATES LLC | $44.03M | 5.38 | 8.84M | +0.3% | +$132,532.73 | 0.03 | |
| Adage Capital Partners Gp L L C | $41.27M | 5.04 | 8.29M | +8.51% | +$3.24M | 0.08 |